

# One Step Test for SARS-CoV-2 Antigen (Colloidal Gold)

User Manual for self-test







Sample extraction



Disposable pipette





User manual





Disposable sampling swab N pc(sterile product CE0197





Hand sanitizer (Not included)

# INTENDED USE

One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is intended for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. This test is used for individuals suspected of COVID-19 within the first seven days of the onset of symptoms, such as headache, fever, cough, sore throat, loss of the sense of smell or taste, shortness of breath, muscle pain. Meanwhile the test can also be applied for individuals without symptoms. Results are for the identification of SARS-CoV-2 antigen. Positive results indicate the presence of SARS-CoV-2 antigens, but individual history and other diagnostic information is necessary for determine infection status. Negative results do not rule out SARS-CoV-2 infection. Negative possibly. If necessary, it should be confirmed by molecular assay. One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) is intended to be used to help the diagnosis of SARS-CoV-2 infection. This test is used for self-test.

#### PREPARING THE TEST



Check integrity of the out package, components and the expiration date.

2.





Read the user manual before starting the test. Check introduction video for more help.

3.



Open the pouch. Check the result window and sample well (s).

# SPECIMEN COLLECTION








Collection and test by caregiver (<18 years, sick, elderly, disabled persons)

Note: Please follow your local guideline for specimen collection.

#### **TEST PROCEDURE**



Pour sample extraction solution into the disposable pipette and place it into the package.



Squeeze the swab tip along the inner wall of the disposable pipette 3 times.

2.



Open the swab packag. Gently insert the tip of the swab into one nostril. Do not insert the swab more than 1.5 cm into your nose.

6.



Tighten the disposable pipette, gently squeeze the disposable pipette and add 2~3 drops of solution into the sample well (s).

3.



Rotate the swab around the inside wall of your nostril at least 4 times. Repeat the same process with the same swab in the other nostril.

7.



10-15 min

Read the result visually in 10~15 min, don't read results after 20 min.

4.



Insert the swab after sampling to the disposable pipette and rotate the swab 10 times in the solution.

8.



Put all of the used test kit contents in the biohazard sample bag provided and put this in household waste. If necessary, discarded all used tests according to local regulations. Wash your hands thoroughly after disposal.

#### **TEST RESULTS**



Positive

# Positive (+):

Both the control line (C) and test line (T) appear indicates the presence of SARS-CoV-2 antigen. Any faint line in the test line (T) should be considered positive.

**Note:** Positive results indicate the very likely infected COVID-19. Contact your doctor or the local health department immediately. Follow the local guidelines for self-isolation and confirmed by a molecular testing method.



Negative

# Negative (-):

Only the control line (C) and no test line (T) appear indicates no SARS-CoV-2 antigen was detected.

**Note:** Negative results indicate the unlikely infected COVID-19. Continue to follow all applicable rules and protective measures when contacting with others. There may be an infection even if the test is negative. If it is suspected, repeat the test after 1 - 2 days or confirmed by a molecular testing method.



Invalid

# اِ

# Invalid:

Control area (C)fails to appear, the test result is invalid. Not enough sample volume or incorrect operation are the likely reasons for an invalid result. Read the instructions again and test with a new test. If the same situation reappears, please stop using this batch of products and contact your doctor or a COVID-19 test center.

#### STORAGE AND STABILITY

Store the test kit at 4-30°C with a valid period of 24 months. Use the test card within 1 hour once the foil pouch is opened.

#### PRINCIPLE

The test uses anti-SARS-CoV-2 nucleocapsid protein (N protein) monoclonal antibody I conjugated with colloidal gold coated on the sample pad, and another anti-SARS-CoV-2 N protein monoclonal antibody II coated on test line. After the samples have been applied to the test strip, the colloidal gold-labelled anti-SARS-CoV-2 N protein monoclonal antibody I bind with SARS-CoV-2 antigens in sample and form marked antigen-antibody complexes. These complexes move to the test card detection zone by capillary action. Then marked antigen-antibody complexes will be captured on test line by anti-SARS-CoV-2 N protein monoclonal antibody II. The color intensity of each test line increases in proportion to the amount of SARS-CoV-2 antigen in sample.

#### **PRECAUTIONS**

- Always keep out of the reach of children. Small parts of the kit can be a choking hazard.
- Sample extraction solution is a phosphate buffer contained low concentration of sodium chloride, Tween, hexadecyl trimethyl ammonium bromide and sodium azide. If extraction solution splashes your body or into eyes, please wash with water.

#### LIMITATIONS

- False-negative result may occur if the level of antigen in sample is below the detection limit of the test or the sample was collected incorrectly.
- 2. The test kit cannot differentiate between SARS-CoV and SARS-CoV-2.
- Clinical diagnosis and treatment cannot be made without consulting with the physician.
- A negative result, from an individual have symptoms similar to COVID-19 beyond seven days should be treated as negative possibly. If necessary, confirmed with the molecular assay.

#### PERFORMANCE CHARACTERISTICS

#### 1 Limit of Detection (LoD)

The LoD for nasal swab was established using heat-inactivated SARS-CoV-2 isolate strain. The strain was spiked with negative human nasal swab into a series of concentrations. The estimated LoD found from the initial two-fold serial dilution test was confirmed by testing 20 replicates.

The confirmed LoD for nasal swab was 200 TCID<sub>50</sub>/mL.

2 Clinical Agreement Study

The clinical performance of One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) was evaluated by testing a total of 480 nasal swab samples. It is compared to the results of RT-PCR assays. Overall study results were shown in the tables below.

Total		BGI's RT-PCR kit		
		positive	negative	subtotal
Getein's kit	positive	165	4	169
	negative	5	306	311
	subtotal	170	310	480

Positive percent agreement (Diagnostic sensitivity) = 165 / (165 + 5) ×100% = 97.06% (95% CI: 93.30%-98.74%)

Negative percent agreement (Diagnostic specificity) =  $306 / (306 + 4) \times 100\% = 98.71\% (95\% CI: 96.73\%-99.50\%)$ 

Total percent agreement =  $(165 + 306) / 480 \times 100\% = 98.13\% (95\% CI: 96.48\%-99.01\%)$ 

#### 3 Analytical Specificity

# 3.1 Cross-Reactivity & Microbial Interference

Each organism and virus was tested in triplicate in the absence and presence of SARS-CoV-2 respectively. According to the test results, there was no cross-reactivity with the following viruses or organisms.

Viruses or organisms	Concentration
Human coronavirus 229E	1 x 10 <sup>5</sup> PFU/mL
Human coronavirus OC43	1 x 10 <sup>5</sup> PFU/mL
Human coronavirus NL63	9.87 x 10 <sup>3</sup> PFU/mL
MERS coronavirus	7930 PFU/mL
	1 x 10 <sup>5</sup> PFU/mL
Adenovirus (e.g. C1 Ad. 71)	
Human Metapneumovirus (hMPV)	1 x 10 <sup>5</sup> PFU/mL
Parainfluenza virus Type 1	1 x 10 <sup>5</sup> PFU/mL
Parainfluenza virus Type 2	1 x 10 <sup>5</sup> PFU/mL
Parainfluenza virus Type 3	1 x 10 <sup>5</sup> PFU/mL
Parainfluenza virus Type 4a	1 x 10 <sup>5</sup> PFU/mL
Influenza A	1 x 10 <sup>5</sup> PFU/mL
Influenza B	2.92 x 10 <sup>4</sup> PFU/mL
Enterovirus	1 x 10 <sup>5</sup> PFU/mL
Respiratory syncytial virus	1 x 10 <sup>5</sup> PFU/mL
Rhinovirus	4.17 x 10 <sup>5</sup> PFU/mL
Haemophilus influenzae	1 x 10 <sup>6</sup> CFU/mL
Streptococcus pneumoniae	1 x 106 CFU/mL
Streptococcus pyogenes	1 x 10 <sup>6</sup> CFU/mL
Candida albicans	1 x 106 CFU/mL
Pooled human nasal wash	14%v/v
Bordetella pertussis	1 x 10 <sup>6</sup> CFU/mL
Mycoplasma pneumoniae	1 x 10 <sup>6</sup> CFU/mL
Chlamydia pneumoniae	1 x 10 <sup>6</sup> CFU/mL
Legionella pneumophila	1 x 10 <sup>6</sup> CFU/mL
Mycobacterium tuberculosis	1 x 10 <sup>6</sup> CFU/mL
Pneumocystis jirovecii	1 x 10 <sup>6</sup> CFU/mL
Pseudomonas Aeruginosa	1 x 10 <sup>6</sup> CFU/mL
Staphylococcus Epidermidis	1 x 106 CFU/mL

#### 3.2 Interferences

The potentially interfering substances that may be found in the upper respiratory tract in symptomatic subjects (including over the counter medications). No false positive or false negative results were seen at the following concentrations.

Potentially Interfering Substances	Concentration
Blood (human)	5%
Mucin	5 mg/mL
Naso GEL (NeilMed)	5% v/v
CVS Nasal Drops (phenylephrine)	15% v/v
Afrin (Oxymetazoline)	15% v/v
CVS Nasal Spray (Cromolyn)	15% v/v
Zicam Cold Remedy	5% v/v
Homeopathic (Alkalol)	10 % v/v
Sore Throat PhenolSpray	15% v/v
Tobramycin	3.3 mg/dL
Mupirocin	0.15 mg/dL
Fluticasone	5%v/v
Tamiflu (Oseltamivir phosphate)	500 mg/dL
Biotin	0.35 mg/dL
Methanol	0.15%w/v
Diphenhydramine	0.0774 mg/dL
Dextromethorphan	0.00156 mg/dL
Dexamethasone	1.2 mg/dL

### 4.Precision

For repeatability study, the agreement percent of both negative samples

and positive samples are 100%. For reproducibility study, the agreement percent of both negative samples and positive samples are 100%.

#### DESCRIPTION OF SYMBOLS USED

Key to symbols used					
***	Manufacturer		Use-by date		
(2)	Do not re-use		Date of manufacture		
[]i	Consult instructions for use	LOT	Batch code		
4C -30C	Temperature limit	IVD	In vitro diagnostic medical device		
Σ	Contains sufficient for <n> tests</n>	EC REP	Authorized representative in the European Community		
*	Keep away from sunlight	<b>®</b>	Do not use if package is damaged		
REF	Catalogue number	<b>†</b>	Keep away from rain		
Į's	For self-testing	₩	Biological risks		

444

Getein Biotech, Inc.

Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China

Tel: +86-25-68568508

Fax: +86-25-68568500

E-mail: tech@getein.com.cn overseas@getein.com.cn

Website: en.bio-qp.com.cn

EC REP CMC Medical Devices & Drugs S.L.

Add: C/ Horacio Lengo Nº 18, CP 29006, Málaga, Spain

Tel: +34951214054

Version: WCG93-DXF-S-03 Last Edition:12/07/2021

Specification (N)	REF
1 T/kit	CG20615
2 T/kit	CG206152
3 T/kit	CG206153
5 T/kit	CG206155
6 T/kit	CG206156
7 T/kit	CG206157
8 T/kit	CG206158
9 T/kit	CG206159
10 T/kit	CG2061510
12 T/kit	CG2061512
15 T/kit	CG2061515
20 T/kit	CG2061520
25 T/kit	CG2061525